These data represent one of the largest clinical development programs to date for adults living with PTSD and a significant development in a therapy area that hasn’t seen a new approval for a ...

According to the letter, the application could not be approved due to lack of substantial efficacy from the submitted studies. The Food and Drug Administration (FDA) has issued a Complete Response ...

Credit: Getty Images. Significant factors limit MDMA’s ability to be used in the treatment of post-traumatic stress disorder. Significant factors limit MDMA’s ability to be used in the treatment of ...

Many people have interpreted as a setback the “no” vote by an advisory committee to the Food and Drug Administration on Lykos Therapeutics’ new drug application for MDMA-assisted psychotherapy for ...

LONDON & NEW YORK, January 07, 2026--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today ...

Myriam Barthes - Journey Clinical, Inc. Good day, ladies and gentlemen, and welcome to this COMPASS Pathways update webinar. [Operator Instructions] As a reminder, this call is being recorded. I would ...

A web of altered neurochemical pathways and physical brain changes result in post-traumatic stress disorder, or PTSD. The interplay between cortisol dysregulation, heightened norepinephrine levels, ...

The results will be used to seek FDA approval of MDMA, also known as ecstasy, as a treatment for post-traumatic stress disorder. Treating post-traumatic stress disorder (PTSD) with a combination of ...

Compass Pathways has navigated to another successful midphase readout, linking its psilocybin therapy and psychological support to improvements in post-traumatic stress disorder (PTSD) in a small ...

Rena Goldman has over a decade of writing and editing experience. She covers health, wellness, mental health, small business, and how politics and policies impact our daily lives. Rena has worked as a ...